Gastroenterology

The AJMC® Gastroenterology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the stomach, digestive tract, colon, and more.

Latest News
June 14th 2025

Upadacitinib Offers Effective Induction for Pediatric Crohn Disease, Safety Profile Requires Scrutiny

June 10th 2025

Protein Signatures for Predicting Future Crohn Disease and Ulcerative Colitis Diagnoses

June 2nd 2025

Stem Cell Transplant Offers Hope for Children With Severe Monogenic IBD

May 23rd 2025

Guselkumab Demonstrates Rapid and Lasting Results in Crohn Disease

May 12th 2025

Evidence Grows for Upadacitinib in Managing Moderate to Severe UC

Video Interviews
View All
May 24th 2025

Innovating IBD Treatment Using Behavioral Health Tactics

March 24th 2025

Elevating Cancer Care Through Personalized Treatment

January 12th 2025

Personalized Medicine in GI Cancer: Transforming Treatment With Technology, Lifestyle Insights

January 4th 2025

Empowering Patients With GI Cancer: Overcoming Immunotherapy Limitations

Continuing Medical Education
View All
June 23rd 2025

Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape

1.0 Credit / Gastroenterology, Immunology, Rare Diseases
June 23rd 2025

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

1.5 Credits / Endocrinology, Diabetes & Metabolism, Gastroenterology
June 23rd 2025

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

1.5 Credits / Gastroenterology, Immunology
June 23rd 2025

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

1.5 Credits / Gastroenterology
June 23rd 2025

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

1.5 Credits / Gastroenterology, Immunology

More News

man with GERD | Image credit: Suttipun - stock.adobe.com
May 6th 2025

Updated Guidelines Aim to Improve GERD Diagnosis and Treatment

Skylar Jeremias
The American Society for Gastrointestinal Endoscopy has issued new guidelines for diagnosing and managing gastroesophageal reflux disease (GERD), with updated recommendations on endoscopy use, lifestyle changes, and endoscopic treatments like transoral incisionless fundoplication.
Digestive tract | Image credit: tract_Grispb - stock.adobe.com
April 23rd 2025

Upadacitinib Shows Promise for Hard-to-Treat Crohn Disease

Skylar Jeremias
Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.
air pollution and gut health | Image credit: Margarita - stock.adobe.com
April 21st 2025

The Hidden Connection Between Air Quality and Gut Health

Skylar Jeremias
Long-term exposure to multiple air pollutants may silently wreak havoc on your gut, significantly increasing the risk of gastrointestinal diseases and underscoring the urgent need for public health policies that clean the air we breathe and protect our digestive health.
women engaging in moderate exercise | Image credit: Rido - stock.adobe.com
April 18th 2025

Understanding How Fitness Affects Digestive Diseases

Skylar Jeremias
Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
healthy diet | Image credit: Rodica Ciorba - stock.adobe.com
April 16th 2025

How Does Diet Influence GI Cancer Outcomes?

Skylar Jeremias
Healthy dietary patterns, rich in fruits, vegetables, whole grains, and legumes, may significantly reduce the risk and mortality of gastrointestinal cancers, while diets high in red and processed meats, alcohol, and sugary beverages can increase these risks.
inflammatory bowel disease | mi_viri - stock.adobe.com
April 10th 2025

The Future of GI Drug Delivery in Managing IBD

Skylar Jeremias
New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential for enhancing targeted treatment and sustained release of medications in the gastrointestinal (GI) tract, particularly for managing inflammatory bowel disease (IBD).
medicine and money for ulcerative colitis | Image credit: gopixa - stock.adobe.com
April 8th 2025

Vedolizumab First Shows Clinical and Economic Advantage in Ulcerative Colitis

Deana Ferreri, PhD
Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative colitis and Crohn disease, and was less costly in ulcerative colitis, according to a real-world economic analysis from the EVOLVE study.
AJMC
April 7th 2025

Outcomes in Patients With IBD Stratified by Risk of Disease Progression

Tao Fan, PhD Jeanne Jiang, MS Chiahung Chou, PhD Henriette Coetzer, MD Kandavadivu Umashankar, MS Ninfa Candela, MD Jason Wagner, PharmD
This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies.
digestive tract | Image credit: Grisp - adobe.stock.com
April 1st 2025

ANTHEM-UC: Icotrokinra (JNJ-2113) Shows Promise for Ulcerative Colitis

Abigail Brooks, MA
Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.
FDA building | Image Credit: © Tada Images - stock.adobe.com
March 21st 2025

Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC

Laura Joszt, MA
Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).
FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
March 21st 2025

FDA Approves Guselkumab for Adult Patients With Crohn Disease

Cameron Santoro
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
doctor nutrion for celiac disease | Image credit: Best - stock.adobe.com
March 19th 2025

Managing Vitamin Deficiencies in Celiac Disease With Tailored Nutrition

Skylar Jeremias
Celiac disease can lead to both disease-related and diet-induced vitamin deficiencies, making it crucial for patients to receive tailored nutritional management to ensure adequate nutritional intake.
smoking and IBS symptoms| Image credit: PR Image Factory - stock.adobe.com
March 18th 2025

Why Is Smoking Cessation So Hard for People With IBS?

Skylar Jeremias
Adults with irritable bowel syndrome (IBS) who smoke may face heightened challenges in quitting due to severe IBS symptoms and anxiety sensitivity, which increase perceived barriers and reinforce the belief that smoking helps relieve negative emotions.
digestive tract | Image credit: eddows - stock.adobe.com
March 14th 2025

Ironwood Announces Rolling Apraglutide NDA Submission for Short Bowel Syndrome

Abigail Brooks, MA
The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.
woman using EEN to help gastro condition | Image credit: eldarnurkovic - stock.adobe.com
March 12th 2025

Clarifying the Role of EEN Diet as Ulcerative Colitis Therapy

Skylar Jeremias
There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to a systematic review.
inflammatory bowel disease | Image credit: Aliaksandr Marko - stock.adobe.com
March 11th 2025

Addressing Disparities in IBD Care to Reduce Costs and Improve Access

Skylar Jeremias
Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments, increasing biosimilar adoption, and implementing policies that reduce financial disparities and improve long-term patient outcomes.
digestive tract | Image credit: Grispb - stock.adobe.com
March 10th 2025

Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease

Deana Ferreri, PhD
Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.
brain gut connection gastroenterology | Image credit: Hermann - stock.adobe.com
March 5th 2025

Understanding the Bidirectional Relationship Between Anxiety and GI, Liver Conditions

Skylar Jeremias
Health care providers must recognize and address the high prevalence of anxiety in gastroenterology (GI) and hepatology outpatients, as its bidirectional relationship with chronic conditions can significantly impact both physical and emotional wellbeing, according to a global review.
man with IBD scratching his eyes | Image credit: sebra - stock.adobe.com
February 24th 2025

Crohn Disease Subtype, Ocular Manifestation Among Risk Factors for EIMs in IBD

Skylar Jeremias
Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the highest risks among those with Crohn disease, ocular manifestations, or right-sided colonic involvement.
AI generated woman with bacterial stomach infection | Miastoks - stock.adobe.com
February 21st 2025

Updated Clinical Guidelines Outline Optimal Treatment of Helicobacter pylori Infection

Tracy Mahvan, PharmD, MBA, BCGP Cassidy Hixon Jewel Jackson
For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.
Image credit: Chinnapong - stock.adobe.com
February 20th 2025

Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Originator in IBD

Deana Ferreri, PhD
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
doctor and social media influencing | Image credit: Nattakorn - stock.adobe.com
February 18th 2025

How Medical Media Is Shaping Gastroenterology and Hepatology

Skylar Jeremias
Medical media is transforming pediatric gastroenterology and hepatology by boosting networking, research visibility, and education, but best practices are essential for clinical use.
digestive tract | Image credit: mi_viri - stock.adobe.com
February 11th 2025

Abstracts Highlight Access Barriers, CV Risks Associated With IBD Care

Skylar Jeremias
Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The Crohn’s & Colitis Congress 2025 explored these access issues as well as the potential cardiovascular complications related to IBD therapies.
ulcerative colitis | Image credit: sdecoret - stock.adobe.com
February 6th 2025

Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment

Skylar Jeremias
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network meta-analysis comparing biologics and small molecules.
gallstones | Image credit: Crystal light - stock.adobe.com
February 4th 2025

PROSPERO Identifies Key Risk Factors for Gallstones in Crohn Disease

Skylar Jeremias
The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition significantly increase the risk of gallstone disease in patients with Crohn disease.
IBD-D | Image credit: eddows - stock.adobe.com
February 3rd 2025

FDA Grants Tentative Approval to Generic Version of Rifaximin for IBS-D

Abigail Brooks, MA
The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.
liver and hepatitis B infection | Image credit: Rasi - stock.adobe.com
February 1st 2025

New AGA Guidelines Recommend Risk-Based Prophylaxis for Hepatitis B Reactivation Monitoring

Skylar Jeremias
The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.
inflammatory bowel disease | Image credit: sdecoret - stock.adobe.com
January 24th 2025

FDA Approves Mirikizumab for Crohn Disease

Skylar Jeremias
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach to now include the full spectrum of inflammatory bowel disease.
guy with stomach discomfort after eating bread, celiac | Image credit: weyo - stock.adobe.com
January 23rd 2025

Gene Variant, Season of Birth Identified as Celiac Disease Risk Factors

Skylar Jeremias
Children born in spring or summer with a specific gene variant may have a higher risk of celiac disease and lower levels of a key protein, according to a study, potentially helping future research on autoimmune diseases.
positive covid-19 test | Image credit: JOE LORENZ DESIGN - stock.adobe.com
January 14th 2025

Study Finds Link Between COVID-19 and Elevated Risk of GI Disorders

Skylar Jeremias
A study found that patients with COVID-19 may have a higher risk of developing new gastrointestinal (GI) disorders compared with matched controls, highlighting the need for further research on long-term GI effects post COVID-19 infection.
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo